
    
      OBJECTIVES:

      I. Determine the efficacy of homoharringtonine administered simultaneously with interferon
      alpha in achieving complete cytogenetic response in patients with chronic myelogenous
      leukemia in chronic phase.

      OUTLINE:

      Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH,
      NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
    
  